KRAS and colorectal carcinoma: Triplets are also being investigated in CodeBreaK 101 with the combination of trametinib, sotorasib, and panitumumab, hoping to achieve even deeper suppression of the co-activated MAPK pathway in KRAS-mutated CRC [125].